Eli Lilly statement on Chinese media report

Eli Lilly statement on Chinese media report
 
We are deeply concerned about the allegations made against Lilly China published on August 21, 2013 in the 21st Century Business Herald.
 
First, there is no former Lilly senior manager in China named Wang Wei; as indicated in the article, it is a fictitious name. However, we were made aware of very similar allegations in 2012 by a former sales manager in the same region. At the time of the allegations, we did an exhaustive investigation to search for any evidence of kickbacks. The investigation was very thorough and included employee interviews, e-mail monitoring, and expense report audits.  Although we have not been able to verify these allegations, we take them seriously, and we are continuing our investigation. 
 
As part of our mission to improve global health, Lilly brings innovative medicines to patients, and also shares important scientific medical information with physicians and scientists for the benefits of their patients. We have processes designed to ensure we implement our programs in accordance with the highest ethical standards and in compliance with the law. Integrity is foremost among the values that have guided Lilly and its employees for more than 137 years.

Suggested Articles

Hecht recently sat down with Fierce Pharma to discuss how Ora supports their customers and site partners.

Alexion Pharmaceuticals names its first chief diversity officer as the rare disease specialist looks to cultivate diversity and inclusion.

BMS executives pointed to upcoming Opdivo data releases, as well as strong demand for other drugs in the portfolio, as reasons for optimism.